Lloyd Johnson - Haemonetics Director
| HAE Stock | USD 75.49 0.89 1.17% |
Insider
Lloyd Johnson is Director of Haemonetics since 2021.
| Age | 66 |
| Tenure | 3 years |
| Address | 125 Summer Street, Boston, MA, United States, 02110 |
| Phone | 781 848 7100 |
| Web | https://www.haemonetics.com |
Lloyd Johnson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Lloyd Johnson against Haemonetics stock is an integral part of due diligence when investing in Haemonetics. Lloyd Johnson insider activity provides valuable insight into whether Haemonetics is net buyers or sellers over its current business cycle. Note, Haemonetics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Haemonetics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Lloyd Johnson over three months ago Acquisition by Lloyd Johnson of tradable shares of Apogee Enterprises subject to Rule 16b-3 |
Haemonetics Management Efficiency
The company has Return on Asset of 0.0609 % which means that on every $100 spent on assets, it made $0.0609 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1298 %, implying that it generated $0.1298 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. As of September 25, 2024, Return On Tangible Assets is expected to decline to 0.05. In addition to that, Return On Capital Employed is expected to decline to 0.07. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 99.5 M, whereas Total Current Assets are forecasted to decline to about 437.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Heidi Tlili | AptarGroup | 49 | |
| Laurent Attias | Alcon AG | 56 | |
| John Knorpp | Merit Medical Systems | N/A | |
| Neil Peterson | Merit Medical Systems | 57 | |
| Eric Conley | Envista Holdings Corp | N/A | |
| CPA Parra | Merit Medical Systems | 46 | |
| Wendy Carruthers | Envista Holdings Corp | 52 | |
| Molly Joseph | West Pharmaceutical Services | 46 | |
| Matt Tomkin | Teleflex Incorporated | N/A | |
| Gayle Sheppard | Envista Holdings Corp | 66 | |
| CCEP CCEP | AtriCure | 52 | |
| Teresa Madden | The Cooper Companies, | 65 | |
| Warner H | The Cooper Companies, | 56 | |
| Jenwei Wu | AptarGroup | 64 | |
| Matthew DellaMaria | AptarGroup | N/A | |
| Kimberly MacKay | West Pharmaceutical Services | 58 | |
| Isabel MareySemper | AptarGroup | 53 | |
| Ines Poschel | Alcon AG | 50 | |
| F Ball | Alcon AG | 64 | |
| Lynn Bleil | Alcon AG | 56 | |
| Michael Onuscheck | Alcon AG | 53 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0609 |
Haemonetics Leadership Team
Elected by the shareholders, the Haemonetics' board of directors comprises two types of representatives: Haemonetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Haemonetics. The board's role is to monitor Haemonetics' management team and ensure that shareholders' interests are well served. Haemonetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Haemonetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stewart Strong, Pres Hospital | ||
| Rajeev Varma, Senior Development | ||
| William Burke, Chief Financial Officer, Executive Vice President | ||
| Olga Guyette, Director Relations | ||
| Carla Burigatto, VP Communications | ||
| Laurie Miller, Senior Officer | ||
| Ronald Gelbman, Interim CEO, Lead Director, Chairman of Governance and Compliance Committee and Member of Audit Committee | ||
| Robert Abernathy, Independent Director | ||
| Ellen Zane, Non-Executive Independent Chairman of the Board | ||
| Claire Pomeroy, Independent Director | ||
| Michelle Basil, Executive Vice President General Counsel | ||
| Christopher Simon, President, Chief Executive Officer, Director | ||
| Catherine Burzik, Independent Director | ||
| Mark Kroll, Independent Director | ||
| James Darecca, Executive Vice President, Chief Financial Officer | ||
| James CPA, Executive CFO | ||
| Jacqueline Scanlan, Senior Vice President - Human Resources | ||
| Josep Llorens, Senior Vice President - Global Manufacturing and Supply Chain | ||
| Farris Maunsell, Chief VP | ||
| Jan MD, Senior Officer | ||
| Richard Meelia, Non-Executive Independent Chairman of the Board | ||
| Anila Lingamneni, Executive Vice President, Chief Technology Officer | ||
| Francis Tan, Sr Planning | ||
| Charles Dockendorff, Independent Director | ||
| Lloyd Johnson, Director | ||
| Michael Coyle, Independent Director |
Haemonetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Haemonetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0609 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 4.74 B | ||||
| Shares Outstanding | 51.18 M | ||||
| Shares Owned By Insiders | 0.87 % | ||||
| Shares Owned By Institutions | 99.13 % | ||||
| Number Of Shares Shorted | 6.09 M | ||||
| Price To Earning | 50.35 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Haemonetics Stock
When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Earnings Share 2.23 | Revenue Per Share 26.255 | Quarterly Revenue Growth 0.08 | Return On Assets 0.0609 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.